Sellas Life Sciences Group, Inc. SLS
We take great care to ensure that the data presented and summarized in this overview for SELLAS Life Sciences Group, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SLS
View all-
Anson Funds Management LP Dallas, TX7.58MShares$15.8 Million1.95% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.84MShares$5.93 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA820KShares$1.71 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA689KShares$1.44 Million0.0% of portfolio
-
Black Rock Inc. New York, NY430KShares$899,4690.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il350KShares$730,4650.0% of portfolio
-
Empery Asset Management, LP New York, NY308KShares$644,6933.71% of portfolio
-
State Street Corp Boston, MA277KShares$578,9900.0% of portfolio
-
Opus Capital Group, LLC240KShares$500,5540.03% of portfolio
-
Northern Trust Corp Chicago, IL164KShares$343,5750.0% of portfolio
Latest Institutional Activity in SLS
Top Purchases
Top Sells
About SLS
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
Insider Transactions at SLS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 12
2025
|
Robert L Van Nostrand Director |
BUY
Open market or private purchase
|
Direct |
10,000
+32.89%
|
$10,000
$1.48 P/Share
|
|
May 30
2025
|
Jane Wasman Director |
BUY
Open market or private purchase
|
Direct |
20,000
+39.68%
|
$20,000
$1.69 P/Share
|
|
May 22
2025
|
Katherine Bach Kalin Director |
BUY
Open market or private purchase
|
Direct |
20,000
+32.79%
|
$20,000
$1.8 P/Share
|
|
Jan 10
2025
|
John Thomas Burns CFO |
BUY
Grant, award, or other acquisition
|
Direct |
194,300
+27.77%
|
-
|
|
Jan 10
2025
|
Dragan Cicic SVP, Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
194,300
+26.95%
|
-
|
|
Jan 10
2025
|
John Varian Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+35.31%
|
-
|
|
Jan 10
2025
|
Katherine Bach Kalin Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+37.31%
|
-
|
|
Jan 10
2025
|
Robert L Van Nostrand Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+35.31%
|
-
|
|
Jan 10
2025
|
Jane Wasman Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+35.31%
|
-
|
|
Jan 10
2025
|
David A Scheinberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+35.13%
|
-
|
|
Jan 10
2025
|
Angelos M. Stergiou President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
500,900
+25.79%
|
-
|
|
Dec 04
2024
|
John Thomas Burns CFO |
SELL
Other acquisition or disposition
|
Direct |
7,165
-6.4%
|
$7,165
$1.13 P/Share
|
|
Dec 04
2024
|
Angelos M. Stergiou President and CEO |
SELL
Other acquisition or disposition
|
Direct |
28,289
-7.32%
|
$28,289
$1.13 P/Share
|
|
Dec 04
2024
|
Dragan Cicic SVP, Chief Development Officer |
SELL
Other acquisition or disposition
|
Direct |
8,256
-6.68%
|
$8,256
$1.13 P/Share
|
|
Jan 22
2024
|
John Thomas Burns CFO |
BUY
Grant, award, or other acquisition
|
Direct |
47,000
+31.56%
|
-
|
|
Jan 22
2024
|
Robert L Van Nostrand Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+36.59%
|
-
|
|
Jan 22
2024
|
John Varian Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+36.59%
|
-
|
|
Jan 22
2024
|
Robert Francomano Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+32.83%
|
-
|
|
Jan 22
2024
|
Jane Wasman Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+36.59%
|
-
|
|
Jan 22
2024
|
Katherine Bach Kalin Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+41.38%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 952K shares |
|---|---|
| Open market or private purchase | 50K shares |
| Other acquisition or disposition | 43.7K shares |
|---|